Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.

Ropa J, Saha N, Hu H, Peterson LF, Talpaz M, Muntean AG.

Haematologica. 2019 Sep 26. pii: haematol.2019.223883. doi: 10.3324/haematol.2019.223883. [Epub ahead of print]

2.

The PAF1c Subunit CDC73 Is Required for Mouse Hematopoietic Stem Cell Maintenance but Displays Leukemia-Specific Gene Regulation.

Saha N, Ropa J, Chen L, Hu H, Mysliwski M, Friedman A, Maillard I, Muntean AG.

Stem Cell Reports. 2019 May 14;12(5):1069-1083. doi: 10.1016/j.stemcr.2019.03.010. Epub 2019 Apr 25.

3.

PAF1 complex interactions with SETDB1 mediate promoter H3K9 methylation and transcriptional repression of Hoxa9 and Meis1 in acute myeloid leukemia.

Ropa J, Saha N, Chen Z, Serio J, Chen W, Mellacheruvu D, Zhao L, Basrur V, Nesvizhskii AI, Muntean AG.

Oncotarget. 2018 Apr 24;9(31):22123-22136. doi: 10.18632/oncotarget.25204. eCollection 2018 Apr 24.

4.

The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.

Serio J, Ropa J, Chen W, Mysliwski M, Saha N, Chen L, Wang J, Miao H, Cierpicki T, Grembecka J, Muntean AG.

Oncogene. 2018 Jan 25;37(4):450-460. doi: 10.1038/onc.2017.337. Epub 2017 Sep 25.

5.

Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.

Chen L, Sun Y, Wang J, Jiang H, Muntean AG.

Oncotarget. 2016 May 3;7(18):25208-23. doi: 10.18632/oncotarget.8199.

6.

Menin-MLL inhibitors block oncogenic transformation by MLL-fusion proteins in a fusion partner-independent manner.

He S, Malik B, Borkin D, Miao H, Shukla S, Kempinska K, Purohit T, Wang J, Chen L, Parkin B, Malek SN, Danet-Desnoyers G, Muntean AG, Cierpicki T, Grembecka J.

Leukemia. 2016 Feb;30(2):508-13. doi: 10.1038/leu.2015.144. Epub 2015 Jun 18. No abstract available.

7.

Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J.

Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26.

8.

Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition.

Chen L, Chen W, Mysliwski M, Serio J, Ropa J, Abulwerdi FA, Chan RJ, Patel JP, Tallman MS, Paietta E, Melnick A, Levine RL, Abdel-Wahab O, Nikolovska-Coleska Z, Muntean AG.

Leukemia. 2015 Jun;29(6):1290-300. doi: 10.1038/leu.2015.18. Epub 2015 Feb 4.

9.

The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.

Murai MJ, Pollock J, He S, Miao H, Purohit T, Yokom A, Hess JL, Muntean AG, Grembecka J, Cierpicki T.

Blood. 2014 Dec 11;124(25):3730-7. doi: 10.1182/blood-2014-01-550079. Epub 2014 Oct 10.

10.

C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.

Collins C, Wang J, Miao H, Bronstein J, Nawer H, Xu T, Figueroa M, Muntean AG, Hess JL.

Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9899-904. doi: 10.1073/pnas.1402238111. Epub 2014 Jun 23.

11.

Mechanisms of mixed-lineage leukemia.

Muntean AG.

Int J Hematol Oncol. 2013 Jun 1;2(3):207-217.

12.

MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.

Muntean AG, Chen W, Jones M, Granowicz EM, Maillard I, Hess JL.

Blood. 2013 Sep 12;122(11):1914-22. doi: 10.1182/blood-2013-02-486977. Epub 2013 Jul 30.

13.

A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.

Wang J, Muntean AG, Wu L, Hess JL.

J Biol Chem. 2012 Dec 21;287(52):43410-6. doi: 10.1074/jbc.M112.423855. Epub 2012 Nov 5.

14.

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, Hartley T, Hess JL, Cierpicki T.

Nat Chem Biol. 2012 Jan 29;8(3):277-84. doi: 10.1038/nchembio.773.

15.

ECSASB2 mediates MLL degradation during hematopoietic differentiation.

Wang J, Muntean AG, Hess JL.

Blood. 2012 Feb 2;119(5):1151-61. doi: 10.1182/blood-2011-06-362079. Epub 2011 Dec 15.

16.

CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.

Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I, Hess JL.

Cancer Cell. 2011 Nov 15;20(5):563-75. doi: 10.1016/j.ccr.2011.09.008.

17.

The pathogenesis of mixed-lineage leukemia.

Muntean AG, Hess JL.

Annu Rev Pathol. 2012;7:283-301. doi: 10.1146/annurev-pathol-011811-132434. Epub 2011 Oct 17. Review.

18.

PAFc, a key player in MLL-rearranged leukemogenesis.

Tan J, Muntean AG, Hess JL.

Oncotarget. 2010 Oct;1(6):461-5.

19.

Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?

Sanders DS, Muntean AG, Hess JL.

Leuk Res. 2011 Mar;35(3):299-300. doi: 10.1016/j.leukres.2010.09.015. Epub 2010 Oct 16. No abstract available.

PMID:
20952059
20.

The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.

Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, Basrur V, Elenitoba-Johnson KS, Hess JL.

Cancer Cell. 2010 Jun 15;17(6):609-21. doi: 10.1016/j.ccr.2010.04.012.

21.

Epigenetic dysregulation in cancer.

Muntean AG, Hess JL.

Am J Pathol. 2009 Oct;175(4):1353-61. doi: 10.2353/ajpath.2009.081142. Epub 2009 Aug 28.

22.

The PHD fingers of MLL block MLL fusion protein-mediated transformation.

Muntean AG, Giannola D, Udager AM, Hess JL.

Blood. 2008 Dec 1;112(12):4690-3. doi: 10.1182/blood-2008-01-134056. Epub 2008 Sep 16.

23.

MLL-AF9 leukemia stem cells: hardwired or taking cues from the microenvironment?

Muntean AG, Hess JL.

Cancer Cell. 2008 Jun;13(6):465-7. doi: 10.1016/j.ccr.2008.05.012.

24.

STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice.

Huang Z, Richmond TD, Muntean AG, Barber DL, Weiss MJ, Crispino JD.

J Clin Invest. 2007 Dec;117(12):3890-9.

25.

Cyclin D-Cdk4 is regulated by GATA-1 and required for megakaryocyte growth and polyploidization.

Muntean AG, Pang L, Poncz M, Dowdy SF, Blobel GA, Crispino JD.

Blood. 2007 Jun 15;109(12):5199-207. Epub 2007 Feb 22.

26.

Transcription factor GATA-1 and Down syndrome leukemogenesis.

Muntean AG, Ge Y, Taub JW, Crispino JD.

Leuk Lymphoma. 2006 Jun;47(6):986-97. Review.

PMID:
16840187
27.
28.

CYR61 (CCN1) is essential for placental development and vascular integrity.

Mo FE, Muntean AG, Chen CC, Stolz DB, Watkins SC, Lau LF.

Mol Cell Biol. 2002 Dec;22(24):8709-20.

Supplemental Content

Loading ...
Support Center